Suzhou Pioneer Pharmaceutical Co., Ltd.

This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA). It consisted of two phases, phase 2 dose exploration trial and phase 3 confirmatory trial.

评价KX-826酊外用治疗中国成年男性雄激素性秃发（AGA）患者的安全性和有效性

评价KX-826酊1.0%在中国成年雄激素性秃发受试者中局部外用多次给药的安全性、耐受性和药代动力学特征。